Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Sistemsko zdravljenje napredovalega diferenciranega raka ščitnice
Authors:ID Grašič-Kuhar, Cvetka (Author)
Files:.pdf PDF - Presentation file, download (508,96 KB)
MD5: 62C3F837C5D47545D1A573C3FCD84778
PID: 20.500.12556/dirros/1314bce4-0d05-4b66-814a-35d1f10c49a3
 
Language:Slovenian
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Diferencirani rak ščitnice predstavlja preko 90 odstotkov raka ščitnice. Nastane iz folikularnih celic ščitnice in spada med visoko ozdravljive rake. Primarno zdravljenje je kirurško, visoko rizični za ponovitev prejmejo še adjuvantno radiojodno terapijo in tiroksin v supresijskem odmerku. Pri 7-23% bolnikov pride do pojava zasevkov v oddaljenih organih (pljuča, skelet). Temelj zdravljenja metastatskega diferenciranega raka ščitnice je radiojodna terapija. Pri pojavu rezistence na radiojodno terapijo je ob napredovanju bolezni sedaj na voljo zdravljenje s tarčnim zdravilom sorafenibom.
Keywords:rak ščitnice, napredovali rak, zdravljenje, preživetje
Publication status:Published
Publication version:Version of Record
Year of publishing:2014
Number of pages:str. 89-91, 118
Numbering:Letn. 18, št. 2
PID:20.500.12556/DiRROS-9075 New window
UDC:616.4-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-7YT5VXTU
COBISS.SI-ID:1963131 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:2898
Downloads:754
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Systemic treatment of advanced differentiated thyroid cancer
Abstract:Differentiated thyroid cancer represents over 90 percents of thyroid cancers. It arises from thyroid follicular cells and is one of highly treatable cancers. Primary treatment is surgical and patients at high risk of carcinoma recurrence also receive adjuvant radioiodine therapy and a suppressive dose of thyroxin. In 7–23% of patients metastases appear in remote organs (lungs, skeleton). The basic treatment for metastatic differentiated thyroid cancer is radioiodine therapy. In case of resistance to radioiodine therapy during disease progression, treatment is now also possible with target medication sorafenib.


Archive

niGradiv

Back